Michelson Diagnostics OCT scanner garners $955k investment
Michelson Diagnostics has gained a $955k investment for its VivoSight optical coherence tomography (OCT) scanners for non-melanoma skin cancer.
Michelson Diagnostics (Orpington, England) has gained a $955k investment for its VivoSight optical coherence tomography (OCT) scanners for non-melanoma skin cancer. Extending the £1.92M investment the scanners received in October 2011, the new investment will further expand sales and support infrastructure in both the US and Europe and comes from shareholders Octopus Investments, Catapult Venture Managers, and individual investors, including London Business Angels.
VivoSight—based on the company's patented multi-beam OCT technology—diagnoses and treats non-melanoma skin cancer noninvasively, enabling clinicians to 'see' under skin surface in real time while conserving healthy tissue. Able to reduce unnecessary surgery, the scanners have already earned CE and FDA regulatory clearance for clinical use in Europe and the US, respectively, and have entered commercial service at dermatology clinics in the US and Germany. In the future, the scanners could guide and monitor next-generation, noninvasive topical treatments for non-melanoma skin cancer currently in clinical development.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!